GlassScriptPhysician profile
Deborah Leigh Copeland
NPI 1316058787
$12,997.66
in general payments reported to CMS, 2019-2025
38 companies · $1,101 in 2025
The $1,101 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,195 · 2020: $2,304 · 2021: $2,556 · 2022: $2,418 · 2023: $1,344 · 2024: $1,081 · 2025: $1,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,525.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,281.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,478.40 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $1,250.62 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,065.02 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $745.78 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $695.13 | 2019-2024 | Arexvy, Shingrix, Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $618.63 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $534.08 | 2020-2023 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $445.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $395.74 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $376.89 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $307.49 | 2021-2025 | |
| Amarin Pharma, INC. | $303.45 | 2019-2021 | |
| Pfizer INC. | $300.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $262.28 | 2019-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Copeland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.